Cisplatin and Emesis: Aspects of Treatment and a New Trial for Delayed Emesis Using Oral Dexamethasone plus Ondansetron Beginning at 16 Hours after Cisplatin

Richard J. Gralla, Cindy Rittenberg, Mel Peralta, Linda Lettow, Michele Cronin

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

The marked progress in controlling emesis caused by cisplatin characterizes the current status of antiemetic treatment for all chemotherapy. Cisplatin has provided a model for antiemetic studies. Strategies for controlling cisplatin-induced emesis are at least as successful when applied to other chemotherapy, and persistent problems such as delayed emesis and the emesis associated with consecutive-day chemotherapy are also similar to or less severe than those observed with cisplatin. The purpose of this report is twofold: first to outline briefly therapy for cisplatin-induced emesis as illustrated by several new studies, and, second, to report on a new trial that incorporates some different strategies in the control of delayed emesis after cisplatin.

Original languageEnglish (US)
Pages (from-to)86-91
Number of pages6
JournalOncology (Switzerland)
Volume53
Issue number1
DOIs
StatePublished - Jan 1 1996

Keywords

  • Cisplatin
  • Delayed emesis
  • Dexamethasone
  • Ondansetron

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cisplatin and Emesis: Aspects of Treatment and a New Trial for Delayed Emesis Using Oral Dexamethasone plus Ondansetron Beginning at 16 Hours after Cisplatin'. Together they form a unique fingerprint.

Cite this